Summary: Somatostatin was first discovered in the hypothalmus and has since been located in many parts of the central and periphefal nervous System, äs well äs in the pancreas and the gastrointestinal tract. Its main biological activity is to inhibit the action of somatotropin (growth hormone, STH, GH) and a number of other hormones. The therapeutic value of somatostatin has been demonstrated in the treatment of both acute bleeding gastric ulcers and acute pancreatitis. In additioii, the measurement of somatostatin in the blood is a useful method for the screening of somatostatin-produeing tumours. This paper reviews the location, action, clinical significance and measurement of somatostatin.
Introduction
" " , . , ",, .".,., of the hypothalamus. The capillanes of the capillary Intensive reseärch has been carried out to identify the plexüs in this region are fenestrated and therefore hormones of the hypothalamus which influence pitüitary , permeable to relatively large molecules. The long portal function. So far, three hypothalamic hormones häve been veiiis of the hypothälamicJiypophyseal portal system idontified and their biological effects in änimals and man drain the capillary plexüs into the sinusoids of the investigated: thyrölib^riii (thyrotropin-releasing hör-ädenohypophysis. By this pathway, the h5 othalamic mone, TRH), identified in 1969 by Guiltemin (1) and hormones control ädenohypophysis hormone secretion Schally (2); Luliberin (luteinizing-hormone-releasing ( fig. 2 ). Certain of these hormones affect more than hormone, LHRH), isolated in 1971 by Schally (3); and one pitüitary hormone: e.g., thyroliberin causes the somatostatin, reported by Guillemiii in 1973 (4) and by release of thyrotropin (thyrotropic hormone, TSH) Schally in 1976 (5). Figure l shows the chemical struc-(l, 2) and prolactin (6); luliberin releases lutropin tures of these three hormones.
(luteinizing hormone, LH) and follitropin (follicleThe tuberohypophyseal neurons are believed to synstimulating hormone, FSH) (3,7), and somatostatin thesize, transport, and release the hypothalamic hör-inhibits the secretion of somatotropin (4) and thyromones into perivascular spaces in the median eminence tropin (8). 
Localization of Somatostatin
Tissue locälization of Somatostatin has been elucidated mainly by immunohistochemistry and by radioimmuno* assay. For this reaspn, the term "spmatostatin-like immunoreactivity" may be more äpprppriate |n this context than "Somatostatin". Somatostatin, which was first discovered in the hypothalamus is now known to be widely distributed throughout the brain (tab. l; fig. 3 ).
- The hormone has also been detected in pancreatic islet cells ) (9) and in the so-called D-cells qf the stomaeh and gut (10-16). Thyroliberin is another peptide which is normally associated with the brain, but which has also been found in the pancreas and in the gastrointestinal tract (17). Conversely, many gastrointestinal peptides such äs substance P (18,19), vasoactive intestinal peptide (VIP) (20,21), neurotensin (22), gastrin (23) and insulin 24) have been isolated from brain tissue.
However, Somatostatin is not restricted to brain and gut. Its presence has been demonstrated in the thyroid, blood, cerebrospinal fluid, amniotic fluid, retina and tumours of the pancreas and gut (see tab. l; fig. 3 ). Intracellularly, Somatostatin has been identified in the Golgi complex (25,26).
The disseminative distribution of Somatostatin suggests a mainly paracrine function for the peptide, i.e. somatostatin acts on neighbouring cells and tissues rather than on some distant target receptors through dissemination of its Signal by the bloodstream (27).
Biosynthesis of Somatostatin
After the discovery of the existence of prohormones äs biosynthetic precursors (e.g.: insulin, glucagon, gastrin, cholecystokinin, parathyrin, 0-melanotropin and j3-endorphin) (see I.e. (28) for review), the acceptance of the formation of a series of peptide hormones from a single precursor by post-translational cleavage has by now become commonplace (29-32). In view of this and the fact that many reports of the occurrence of Somatostatin are based on immunological evidence, it is hardly surprising that there is some conflict äs to the exact nature of the peptide, but that there is some consensus on its biosynthesis in the pancreas and hypothalamus. The primary structure of a big-somatostatin was first described in 1980 byPradayrol et al. (15). The big-somatostatin from porcine intestine is an octacosapeptide, the so-called "somatostatin-28", and its region 15-28 represents the previously known tetradecapeptide Somatostatin (somatostatin-14). Bigsomatostatins from both pig and sheep hypothalamus were found to have identical structures (33, 34) .
Another big-somatostatin, a pentacosapeptide (somatostatin-25) was found by Bohlen et al. 1980 (33) . this may be a further intermediate of the pathway to the matured somatostatin-14. The N-terminal extension in big-somatostatin is linked to the tetradecapeptide through an Arg-Lys peptide bond, which is the characteristic bond susceptible to cleavage by trypsin-like enzymes. Both somatostatin-28 and somatostatin-14 are released from the median eminence synaptosomes (35) , and it has been shown that subcellular fractions of the hypothalamus can convert somatostatin-28 to somatostatin-14 (36).
Recent evidence from three independent groups has demonstrated the existence of mRNA coding for a precursor of Somatostatin in angler fish pancreas (37) (38) (39) (40) . Moreover, the complete amino acid sequence of this preprosomatostatin has been deduced from sequence analyses of cloned cDNA (37, 39) . This precursor contains a Signal peptide which may be released during the transit into the endoplasmic reticulum. The resultant pancreatic prosomatostatin would be approximately 97 amino acid residues with M T = 10600 and has the somatostatin-28 at the COOH-terminus (37).
In hypothalamic extracts, a 15000 M r precursor of the tetradecapeptide Somatostatin has been characterized (41, 42) . In addition, a hypothalamic extract containing protease(s) capable of selectively converting this 15000 precursor into somatostatin-14 has also been described (43) .
In conclusion, to date, there is no clear evidence that somatostatin-14 is formed from somatostatin-28 and not from another intermediate within the event of posttranslational modification.
Catabolism of Somatostatin
Specific proteolytic enzymes have been described for the degradation of other regulatory peptides such äs luliberin and thyroliberin (44) (45) (46) . In the brain, somatoŝ tatin may be cleaved by an indigenous neutral endopeptidase (cathepsin M) with speciilcity for Trp-8/Lys-9 (47). Experiments on Somatostatin analogues have shown that the amino acid sequence from 7-10 is important for biological activity (48) . It is therefore possible that the cleavage of Somatostatin by cathepsin-M is of real catabolic significance. Intravenous injection of Somatostatin is followed by a rapid disappearance of the peptide from the blood. The half-life öf Somatostatin in man has been calculated to be 1.7 min by radioimmüno-assay and 1.9 min by radioreceptorassay (49, 50) äs compared to the 1.1 min Md 3.3 min, respectively, repprted by Sheppardet al. (51) . In the rat, the half life of somatostatin-28 is significantly longer thän that of somatostatin44 (52) . The mechaiiisms iiivolved in this rapid disappearance from the blöodstream are not clear. The most likely sites for elimination and excretion of hypothalamic hormones are: -elimination by circulating peptidases, -distribution and binding to receptor sites in various tissue beds, -elimination by the liver and kidneys. It has been shown by McMartin & Purdon (53) that a plasma aminopeptidase can convert Somatostatin to a biologically active peptide (des-Ala-l)-somatostatin. In a recent report, the disappearance of tritiated Somatostatin from the blood of rats after intravenous injection was demonstrated by the uptake of 70% of the label in the large peripheral tissues such äs muscle, skin and intestine (54) . In the same report, it was stated that less than 10% of the injected label was recovered from the liver and kidneys of the rats. More experiments will be required before the true role of enzymic degradation in the removal of Somatostatin from the blood can be elucidated.
Action of Somatostatin
Somatostatin-28 and somatostatin-14 Before the numerous effects of Somatostatin are described, two questions have to be raised: If somatpstatin^28 is an intermediate of the mature somatostatin-14, the big-somatöstätin should haVe less biological activity than somatostatin-14. Sbmatostatin=28, however, shows equipotency with somatostatin-14 in the Inhibition of somatotropin änd^röläcthi on a molar basis in vitro (SS). On a molar basis, somatostatin-28 has been found to be twice äs active äs somatostatin-14 in inhibiting plasma glucagon and 10 times more active in inhibiting plasma Insulin in the pancreas (SS).
Other comparative studies support these results and also report somatostatin-28 to be a more potent inhibitor of somatotropin in man (56, 57) . These differences in the inhibitory power of the two peptides suggest that somatostatin-28 is not only a presumable intermediate of somatostatin-14. A factor contributing in pärt to the more potent biological activity of somatostatin-28 could be the longer half life of the larger peptide (52).
Mode of action Investigations on the somatostatin receptors in rat pituitary tumour cell membrane were first performed by Schonbrunn and Tashjian Jr. (58). They described receptor sites for somatostatin and found that pnly those cell strains which had somatostatin receptors could respond to the hormone. In addition, the number of somatostatin receptors was modulated by thyroliberin (59) . From other hormones» for example, insulin, it is known that the number of receptor sites in a cell is regulated by the hormone itself (60) . Binding of somatostatin to pituitary plasma membrane has also been reported (61) . Recently, Srikant &Patel demonstrated that there are different receptors for somatostatin-28 and somatostatin-14 in the normal rat pituitary and cerebral cortex (62, 63) . In comparison to somatostatin-14, somatostatin-28 shows a higher affinity fof pituitary receptors than for cerebral cortex receptors. A" specific somatostatin binding factor in the cytosol of the dark islets cell area of the chicken pancreas has beeil detiionstrated (64 3 65). Another group (66) found a somatostatin binding protein while investigating a number of tissues (mainly from the rat). In both species, specificity of binding was demonstrated. However, differences in the data reported suggest differences in the näture of the somatostatin binding. Secretion vesicles isolated from pancreas islet cells have also been shown to exhibit somatostatin binding (67) . It therefore appears that there are specific binding sites in the somatostatin target tissue^ but its exact nature and role in the Initiation of the biological response are still unclear. Inhibition generated by somatostatin is accoinpanied by an intracellular decrease in cyclic AMP levels (68, 69) and an increäse of cyclic GMP, respectively (70), Moreover, somatostatin specifically inhibits the cyclic AMP-dependent protein kinase activity of secretion vesicles isolated from pancreatic islets and the anterior pituitary (71).
Pituitary hormones
Somatostatin inhibits the secretion of somatotropin in animals and in man after virtually all known physiological and pharmacological Stimuli, e.g., arginine (72), L-dopa (72), insulin-induced hypoglycaemia (73, 74) , sleep in normal subjects (75) and in patients with somatotropin-producing pituitary tumours äs in acrpmegaly (74, 76) . Stimulation of thyrotropin by thyroliberin can be abolished by somatostatin (8).
There is no effect on the thyroliberin-induced prolactin secretion in vivo, but an Inhibition of prolactin secretion in vitro has been achieved (77) . Under pathological conditions, somatostatin lowers prolactin levels in patients with acromegaly, but not in normal subjects (78) .
However, these results were not supported by other authors (74) . In man, normal corticotropin levels are not influenced by somatostatin (74, 79) , but the elevated corticotropin levels in patients with Cushing's disease otNelson's disease are lowered by somatostatin infusion (80) (81) (82) . Lutropin and follitropin show no response to somatostatin (79) .
Endocrine pancreas
In l973,Alberti et al. (83) reported that plasma insulin levels were decreased after somatostatin infusion.'The säme effect on glucagon has also been described (84, 85).
In normal man, infusioii of somatostatin lowers plasma glucose levels. This fact indicates the important physiologicäl role of glucagon in glucose homeostasis (86) . The pancreatic polypeptide produced by the F-cells (87) in the pancreatic islets is also suppressed by somatostatin (88) . Figure 4 summarizes the influence of somatostatin on glucose homeostatis.
Exocrine pancreas and gastrointestinal tract Somatostatin has a strong effect on various gastrointestinal hormones and the function of the digestive System. For example, somatostatin inhibits the releäse of gastrin (89, 90) , pepsifi secretion (91), cholecystokinin-pancreozymin (92), secretin (93) , motilin (94) and VIP (vasoäctive intestinal peptide) in VIP-producing tumours (95) . Conversely, experiments on isolated perfused pancreas have shown that somatostatin releäse is stimulated by gastrointestinal peptides like GIP (gastric inhibitory peptide), VIP, glucagon, glucose and arginine (96) (97) (98) (99) . Somatostatin may also reduce duodenal motility (100), gall bladder contractions (92) and gastric emptying (93) . Splanchnic blood flow is surprisingly reduced during continuous intravenous somatostatin infusion in man and animals (101) (102) (103) (104) .
Adrenal gland It has been reported that somatostatin inhibits reninantiotensin-aldosterone adrenal cortex Stimulation in vivo (105) (106) (107) . Since glomerulosa cells from the adrenal cortex seem to be responsible for aldosterone production (108), cells were isolated from the bovine adrenal cortex, and in vitro Stimulation by corticotropin and the influence of added Somatostatin were measured by aldosterone determination (109) . The results indicated that the inhibitory effect of Somatostatin cannot be evaluated in the bovine aldosterone-producing System in vitro.
Other effects of Somatostatin The concept that Somatostatin is a general inhibitory hormone (l 10) cannot be applied to its effect on mast cells. Here, Somatostatin causes a histamine release in vitro (l 14). Furthermore, in vivo studies have shown that Somatostatin enforces the passive cutaneous anaphylaxis in sensitized rats at doses greater than 1 1/1(115).
Usadel and collaborators found that Somatostatin treatment led to an increase in the survival rate in phalloidinintoxicated rats (l 16), and Szabo & Usadel have postulated that this cytoprotective effect is caused via a systemic organoproteetipn (117) and vasculöprotectiqri (118). The beneficial effect of Somatostatin was also seen in experimental adrenal and lurig injuries (l 19) äs well äs in various shock syndromes ' (120) . The mode of these actions needs further investigation.
Clinical Importance
Influence in pathogenesis After discovering the inhibitory effect of Somatostatin on glucose and insulin, clinical 1 studies were performed in order to evaluate the importance of this peptide in diabetes mellitus. Somatostatin lowers blopd glucose levels in patients with diabetes mellitus and in normal subjects (121) (122) (123) . Via the artificial pancreas somatostatin is able to reduce the requirement of insulin in more than 70% öf patients with juvenüe diabetes (124 analogue, without the general inhibiting potency of somatostatin, could play a role in diabetes treatment (125) . There is also some indication that the hormone may be involved in the pathogenesis of diabetes mellitus. In the pancreatic islets of both patients with juvenile diabetes and in rats with diabetes induced by streptozotocin, a hypertrophy and hyperplasia of D-cells containing somatostatin has been found (126) . Elevated somatostatin and glucagon release were observed in isolated pancreatic islets from streptozotocin diabetic rats (127) (128) (129) . D-cell hyperplasia in diabetes could be interpreted s an ineffective attempt to prevent the glucagon hypersecretion by elevated local somatostatin production (126) . In the gastrointestinal tract, somatostatin inhibits gastrin secretion (89) . The somatostatinproducing D-cells are located in close proximity to the gastrin-producing G-cells (127) . In patients with duodenal ulcers, a decrease in D-cell numbers of up to 70% has been found in the mucosa (128, 129) .
A short time after the discovery of somatostatin, its effect on patients suffering from acromegaly was tested. Several groups reported a dose-dependent fall in the plasma level of somatotropin (74, 76, 78) . However, after stopping somatostatin infusion, elevated somatotropin levels returned.
Somatostatinoma
The pancreas has a great potential for tumour formation. Most tumours are derived from the exocrine pancreas. However, an increasing number from the endocrine pancreas have been identified in the past 25 years. Recently, somatostatin-producing tumours, somatostatinomas, have been found in the pancreas (ISO-IS?), duodenum (138) , and jejunum (139) . Ectopic productiori of somatostatin by a cultured human pulmonary small cell carcinoma has also been observed (140) . Endocrine and exocrine pancreatic insufficiency, steatorrhea, diabetes mellitus, and cholelithiasis in the presence of a duodenal tumour suggest sbmatostatinpma (134) . Elevated plasma somatostatin and immunohistochemical examination of the tumour tissue can confirm the somatostatinoma diagnosis.
Clinical Somatostatin Treatment
Using experimental uleer models (141 ,-142), somatostatin was shown to be effective, s the permanent infusion of somatostatin in patients suffering from bleeding gastric lcers stopped bleeding within 6 to 8 hours (143, 144) .
A randomized controlled trial showed somatostatin to be m re effective than cimetid ne in stopping the bleeding from a peptic ulcer (145) .
Acute pancreatitis is also a conceivable candidate for somatostatin treatment. In experimentally induced haemorrhagic pancreatitis in dogs, somatostatin caused a remarkable reduction in the clinical Symptoms (146) . Prophylactic infusion of somatostatin before the Start of an Operation on the pancreas reduced the postoperative complications (147) . Also, two studies have shown an impressive recovery from acute pancreatitis after treatment with somatostatin (148, 149) . For further investigation on somatostatin treatment in acute pancreatitis, a multicentre double-blind trial was started in 1980. The results will be reported in 1982 (150) .
Detection of Somatostatin
If a clinician is presented with a tumour which produces neither insulin, gastrin, nor glucagon, it is recommended by the German Endocrine Society that the plasma levels of somatostatin be measured (151) .
Several radioligand binding assays for somatostatin measurement have been described (49, 50, (152) (153) (154) (155) (156) (157) (158) (159) (160) (161) (162) .
Normal somatostatin plasma levels in man are in the r nge of 40 ng/1 (50). With immunohistochemical methods, e.g., peroxidase-antiperoxidase technique (163, 164) , somatostatin can be detected in the tissue. The distribution of somatostatin in the pancreatic islet is shown in figure 5.
- 
Conclusion
Somatostatin is involved in the regulation of somatotropin secretion in the pituitary and may play a fundamental role in glucose homeostatis and assimilation of nutrients. At the present time, little is known about the ac on of somatostatin in the central nervous System (165) .
The peptide has a beneficial effect in a variety of illnesses, in particular, bleeding gastric ulcers and various experimental organ lesions, e.g., liver, lung, adrenal and shock syndromes. It is likely that the numerous regulatory effects of the peptide will only be properly integrated and understood when the events occurring in the cell after the ligandreceptor interaction are better known at a molecular level.
